Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neumora Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26 | Direct | 80,000 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 20:21 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001610717-26-000170 · form4.xml · derivative · entry 1 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-05-26 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-079918 · ownership.xml · derivative · entry 5 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-05-27 F5 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079918 · ownership.xml · derivative · entry 4 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079918 · ownership.xml · derivative · entry 3 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,455 Underlying: Common Stock · 46,455 shares Expires 2033-09-14 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079918 · ownership.xml · derivative · entry 2 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079918 · ownership.xml · derivative · entry 1 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,455 shares Expires 2033-09-14 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022318 · ownership.xml · derivative · entry 4 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022318 · ownership.xml · derivative · entry 3 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,455 Underlying: Common Stock · 46,455 shares Expires 2033-09-14 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,571 | Not disclosed Strike: $9.95 | Not disclosed |
DisclosureSEC source: 0000950170-25-022318 · ownership.xml · derivative · entry 2 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,455 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-022318 · ownership.xml · derivative · entry 1 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,455 shares Expires 2023-09-14 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:14 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 28,571 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001610717-24-000336 · form4.xml · derivative · entry 2 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-12 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:14 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantCommon Stock | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000336 · form4.xml · nonDerivative · entry 1 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 21:52 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 46,455 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000283 · form4.xml · derivative · entry 1 Halawa Alaa · CIK 0001992622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,455 Underlying: Common Stock · 46,455 shares Expires 2033-09-13 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.